Teva Pharmaceutical Industries Ltd. submitted an abbreviated new drug application to the U.S. FDA to market the generic version of Novo Nordisk A/S' Victoza diabetes drug in the U.S.

Teva believes it is the first applicant to file the application for the drug's generic version. If approved, the company will have 180 days of generic market exclusivity.

The Victoza injection is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.